• RR exenatide BID vs. all placebo or comparator studies

Per FDA guidance, if upper limit of 95% CI <1.3 a post-marketing safety study may not be required; ≥1.3 to <1.8 a post-marketing study may be required to demonstrate <1.3, ≥1.8 large safety study may be required prior to approval.